- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Nanomaterials
Volume 2012 (2012), Article ID 831263, 10 pages
Nanostructured Surfaces to Target and Kill Circulating Tumor Cells While Repelling Leukocytes
Department of Biomedical Engineering, Cornell University, Ithaca, NY 14853, USA
Received 19 November 2012; Accepted 5 December 2012
Academic Editor: Haiyan Li
Copyright © 2012 Michael J. Mitchell et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- C. L. Chaffer and R. A. Weinberg, “A perspective on cancer cell metastasis,” Science, vol. 331, no. 6024, pp. 1559–1564, 2011.
- A. D. Hughes and M. R. King, “Nanobiotechnology for the capture and manipulation of circulating tumor cells,” WIREs Nanomedicine and Nanobiotechnology, vol. 4, no. 3, pp. 291–309, 2011.
- L. M. Coussens and Z. Werb, “Inflammation and cancer,” Nature, vol. 420, no. 6917, pp. 860–867, 2002.
- A. F. Chambers, G. N. Naumov, S. A. Vantyghem, and A. B. Tuck, “Molecular biology of breast cancer metastasis. Clinical implications of experimental studies on metastatic inefficiency,” Breast Cancer Research, vol. 2, no. 6, pp. 400–407, 2000.
- I. C. MacDonald, A. C. Groom, and A. F. Chambers, “Cancer spread and micrometastasis development: quantitative approaches for in vivo models,” BioEssays, vol. 24, no. 10, pp. 885–893, 2002.
- R. C. Young, R. F. Ozols, and C. E. Myers, “The anthracycline antineoplastic drugs,” The New England Journal of Medicine, vol. 305, no. 3, pp. 139–153, 1981.
- J. Bouma, J. H. Beijnen, A. Bult, and W. J. M. Underberg, “Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties,” Pharmaceutisch Weekblad, vol. 8, no. 3, pp. 109–133, 1986.
- N. Osheroff, A. H. Corbett, and M. J. Robinson, “Mechanism of action of topoisomerase II-targeted antineoplastic drugs,” Advances in Pharmacology, vol. 29, pp. 105–126, 1994.
- L. H. Reddy, “Drug delivery to tumours: recent strategies,” Journal of Pharmacy and Pharmacology, vol. 57, no. 10, pp. 1231–1242, 2005.
- A. Fritze, F. Hens, A. Kimpfler, R. Schubert, and R. Peschka-Süss, “Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient,” Biochimica et Biophysica Acta, vol. 1758, no. 10, pp. 1633–1640, 2006.
- M. Saad, O. B. Garbuzenko, E. Ber et al., “Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging?” Journal of Controlled Release, vol. 130, no. 2, pp. 107–114, 2008.
- E. H. Herman, A. Rahman, and V. J. Ferrans, “Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation,” Cancer Research, vol. 43, no. 11, pp. 5427–5432, 1983.
- R. Krishna, N. McIntosh, K. W. Riggs, and L. D. Mayer, “Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion,” Clinical Cancer Research, vol. 5, no. 10, pp. 2939–2947, 1999.
- A. Gabizon, H. Shmeeda, and Y. Barenholz, “Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies,” Clinical Pharmacokinetics, vol. 42, no. 5, pp. 419–436, 2003.
- H. D. Han, A. Lee, T. Hwang et al., “Enhanced circulation time and antitumor activity of doxorubicin by comblike polymer-incorporated liposomes,” Journal of Controlled Release, vol. 120, no. 3, pp. 161–168, 2007.
- B. Čeh, M. Winterhalter, P. M. Frederik, J. J. Vallner, and D. D. Lasic, “Stealth liposomes: from theory to product,” Advanced Drug Delivery Reviews, vol. 24, no. 2-3, pp. 165–177, 1997.
- W. J. Allard, J. Matera, M. C. Miller et al., “Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases,” Clinical Cancer Research, vol. 10, no. 20, pp. 6897–6904, 2004.
- S. Maheswaran and D. A. Haber, “Circulating tumor cells: a window into cancer biology and metastasis,” Current Opinion in Genetics and Development, vol. 20, no. 1, pp. 96–99, 2010.
- G. S. Kansas, “Selectins and their ligands: current concepts and controversies,” Blood, vol. 88, no. 9, pp. 3259–3287, 1996.
- J. Li and M. R. King, “Adhesion receptors as therapeutic targets for circulating tumor cells,” Frontiers in Oncology, vol. 2, article 79, 2012.
- H. Läubli and L. Borsig, “Selectins promote tumor metastasis,” Seminars in Cancer Biology, vol. 20, no. 3, pp. 169–177, 2010.
- T. Krause and G. A. Turner, “Are selectins involved in metastasis?” Clinical and Experimental Metastasis, vol. 17, no. 3, pp. 183–192, 1999.
- S. Gout, P. L. Tremblay, and J. Huot, “Selectins and selectin ligands in extravasation of cancer cells and organ selectivity of metastasis,” Clinical and Experimental Metastasis, vol. 25, no. 4, pp. 335–344, 2008.
- T. A. Springer, “Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm,” Cell, vol. 76, no. 2, pp. 301–314, 1994.
- M. J. Mitchell and M. R. King, “Shear-induced resistance to neutrophil activation via the formyl peptide receptor,” Biophysical Journal, vol. 102, no. 8, pp. 1804–1814, 2012.
- M. J. Mitchell, C. S. Chen, V. Ponmudi, A. D. Hughes, and M. R. King, “E-selectin liposomal and nanotube-targeted delivery of doxorubicin to circulating tumor cells,” Journal of Controlled Release, vol. 160, no. 3, pp. 609–617, 2012.
- S. Amselem, R. Cohen, S. Druckmann et al., “Preparation and characterization of liposomal doxorubicin for human use,” Journal of Liposome Research, vol. 2, no. 1, pp. 93–123, 1992.
- G. Haran, R. Cohen, L. K. Bar, and Y. Barenholz, “Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases,” Biochimica et Biophysica Acta, vol. 1151, no. 2, pp. 201–215, 1993.
- A. N. Lukyanov, T. A. Elbayoumi, A. R. Chakilam, and V. P. Torchilin, “Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody,” Journal of Controlled Release, vol. 100, no. 1, pp. 135–144, 2004.
- J. H. Myung, K. A. Gajjar, R. M. Pearson, C. A. Launiere, D. T. Eddington, and S. Hong, “Direct measurements on CD24-mediated rolling of human breast cancer MCF-7 cells on E-selectin,” Analytical Chemistry, vol. 83, no. 3, pp. 1078–1083, 2011.
- Z. Huang and M. R. King, “An immobilized nanoparticle-based platform for efficient gene knockdown of targeted cells in the circulation,” Gene Therapy, vol. 16, no. 10, pp. 1271–1282, 2009.
- D. Lee, J. B. Schultz, P. A. Knauf, and M. R. King, “Mechanical shedding of L-selectin from the neutrophil surface during rolling on sialyl lewis x under flow,” The Journal of Biological Chemistry, vol. 282, no. 7, pp. 4812–4820, 2007.
- X. Yin, K. Rana, V. Ponmudi, and M. R. King, “Knockdown of fucosyltransferase III disrupts the adhesion of circulating cancer cells to E-selectin without affecting hematopoietic cell adhesion,” Carbohydrate Research, vol. 345, no. 16, pp. 2334–2342, 2010.
- M. B. Kim and I. H. Sarelius, “Distributions of wall shear stress in venular convergences of mouse cremaster muscle,” Microcirculation, vol. 10, no. 2, pp. 167–178, 2003.
- K. Rana, C. A. Reinhart-King, and M. R. King, “Inducing apoptosis in rolling cancer cells: a combined therapy with aspirin and immobilized TRAIL and E-selectin,” Molecular Pharmaceutics, vol. 9, Article ID 120702, 2012.
- A. D. Hughes and M. R. King, “Use of naturally occurring halloysite nanotubes for enhanced capture of flowing cells,” Langmuir, vol. 26, no. 14, pp. 12155–12164, 2010.
- B. T. Greene, A. D. Hughes, and M. R. King, “Circulating tumor cells: the substrate of personalized medicine?” Frontiers in Oncology, vol. 2, article 69, 2012.
- A. D. Hughes, J. Mattison, L. T. Western, J. D. Powderly, B. T. Greene, and M. R. King, “Microtube device for selectin-mediated capture of viable circulating tumor cells from blood,” Clinical Chemistry, vol. 58, no. 5, pp. 846–853, 2012.
- C. G. Begley, A. F. Lopez, N. A. Nicola, et al., “Purified colony-stimulating factors enhance the survival of human neutrophils and eosinophils in vitro: a rapid and sensitive microassay for colony-stimulating factors,” Blood, vol. 68, no. 1, pp. 162–166, 1986.